Further research is needed to fully understand the metabolic implications of ADP400 treatment and the details mechanisms by which peripheral adiponectin receptor disruption affects adiponectin-related metabolic function in the brain and hence contributes to AD-like pathology in the hippocampus. The gene discussed is ADIPOQ; the disease is Alzheimer disease.